Evotec (NASDAQ:EVO) Hits New 1-Year Low – Here’s Why

Shares of Evotec AG (NASDAQ:EVO) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $2.15 and last traded at $2.16, with a volume of 106040 shares trading hands. The stock had previously closed at $2.43.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Finally, HC Wainwright began coverage on Evotec in a research note on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price target for the company. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Evotec currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Evotec Trading Down 11.2%

The company has a 50 day moving average of $2.83 and a 200-day moving average of $3.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68.

Evotec (NASDAQ:EVO) last released its earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $297.02 million during the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%. As a group, analysts predict that Evotec AG will post -0.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Evotec

Several institutional investors have recently modified their holdings of the company. Optiver Holding B.V. boosted its stake in Evotec by 598.4% during the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after purchasing an additional 242,973 shares during the period. WCM Investment Management LLC raised its position in Evotec by 12.1% in the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after acquiring an additional 67,917 shares in the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Evotec in the 1st quarter worth approximately $28,000. SmartHarvest Portfolios LLC acquired a new stake in Evotec during the first quarter valued at approximately $44,000. Finally, XTX Topco Ltd boosted its holdings in Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after buying an additional 3,709 shares in the last quarter. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.